Scribe Therapeutics Management
Management criteria checks 3/4
Scribe Therapeutics' CEO is Benjamin Oakes, appointed in Jun 2017, has a tenure of 9.08 years. total yearly compensation is $1.59M, comprised of 32.2% salary and 67.8% bonuses, including company stock and options. directly owns 3.13% of the company’s shares, worth $7.09M. The average tenure of the management team and the board of directors is 4.3 years and 5.3 years respectively.
Key information
Benjamin Oakes
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 32.16% |
| CEO tenure | 9.1yrs |
| CEO ownership | 3.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$36m |
| Dec 31 2025 | US$2m | US$511k | -US$22m |
Compensation vs Market: Benjamin's total compensation ($USD1.59M) is about average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Insufficient data to compare Benjamin's compensation with company performance.
CEO
Benjamin Oakes (37 yo)
Dr. Benjamin L. Oakes, Ph D., Co-Founded Scribe Therapeutics Inc in June 2017 and its President, Chief Executive Officer and Director since June 2017. He also served as its Chief Financial Officer until Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | US$1.59m | 3.13% $ 7.1m | |
| Chief Financial Officer | 4.6yrs | US$984.71k | 0% $ 0 | |
| Chief Operating Officer | no data | US$787.60k | 0.19% $ 429.7k | |
| Co-Founder & Scientific Advisor | no data | no data | 3.73% $ 8.4m | |
| Co-Founder & VP of External Innovation | no data | no data | 3.24% $ 7.3m | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Head of Intellectual Property | no data | no data | no data | |
| Senior Vice President of Development | less than a year | no data | no data | |
| Secretary | no data | no data | no data | |
| VP & Controller | 4.3yrs | no data | no data |
Experienced Management: SCTX's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | US$1.59m | 3.13% $ 7.1m | |
| Independent Director | 5.3yrs | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 5.3yrs | no data | no data |
Experienced Board: SCTX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/24 19:12 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scribe Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.